ACUT (Accustem Sciences) Cash And Cash Equivalents : $0.01 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Cash And Cash Equivalents?

Accustem Sciences's quarterly cash and cash equivalents declined from Jun. 2024 ($0.05 Mil) to Sep. 2024 ($0.04 Mil) but then stayed the same from Sep. 2024 ($0.04 Mil) to Dec. 2024 ($0.01 Mil).

Accustem Sciences's annual cash and cash equivalents declined from Dec. 2022 ($0.73 Mil) to Dec. 2023 ($0.02 Mil) and declined from Dec. 2023 ($0.02 Mil) to Dec. 2024 ($0.01 Mil).

Accustem Sciences Cash And Cash Equivalents Historical Data

The historical data trend for Accustem Sciences's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Cash And Cash Equivalents Chart

Accustem Sciences Annual Data

Trend

Dec22

Dec23

Dec24

Cash And Cash Equivalents

0.73

0.02

0.01

Accustem Sciences Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial							0.02	0.01	0.05	0.04	0.01

Accustem Sciences Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Accustem Sciences (OTCPK:ACUT) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Accustem Sciences Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Accustem Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Penn Plaza, Suite 1954, Floor 19th, New York, NY, USA, 10001

Website

https://www.accustem.com

Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.